Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice

Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patients with relapsed or refractory (R/R) M...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Formaat:	Artigo
Taal:	Russo
Gepubliceerd in:	"Consilium Medicum" Publishing house 2021-07-01
Reeks:	Терапевтический архив
Onderwerpen:	ibrutinib mantle cell lymphoma real-world practice refractory relapsed
Online toegang:	https://ter-arkhiv.ru/0040-3660/article/viewFile/76311/56902
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!